lmf1264: I wonder whether this controversy will impact NAFDAC's upcoming decision in July as to whether to extend the two year temporary approval of Nicosan?
Likewise, I wonder whether this fiasco constitutes a breach of the terms of the original license of Nicosan from NIPRID to Xechem? (Surely, that license contains some requirement that Xechem proceed with the production of Nicosan in "good faith.")
I would not be surprised if Xechem ultimately loses its rights in Nicosan.
And frankly, if present management is hell-bent on screwing the retail investors -- and lacks the competence to effectively provide Nicosan to SCD patients -- I will shed no tears if the Nigerian Government takes back the rights to this drug.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.